Wei Zhang

Also affiliated with Nanjing University of Chinese Medicine, Central South University, Hunan University, Second Military Medical University, Nantong University, Wuhan University, Affiliated Hospital of Nantong University, Hunan Provincial Center for Disease Control and Prevention, Changhai Hospital, Stomatology Hospital, Wuhan Third Hospital, National Cancer Institute, Center for Cancer Research, Third Xiangya Hospital, Second Affiliated Hospital of Nantong University, Wake Forest University

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer”.

Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359231217959

N/A

0.315DataRank · unranked

5 citations

Chance H. Bloomer, Elena Gavrila, JOHN MASON KALADA, Mark Chang, Rediet R. Gebeyehu +12 more

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

iScience(2025)10.1016/j.isci.2025.112283

N/A

0.240DataRank · unranked

3 citations

Li Qi, Zach Sergi, Guangyang Yu, Olga Kim, Peng Lu +20 more